Cargando…

Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018

BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aksnes, Brooke Noel, Walldorf, Jenny A., Nkwenkeu, Sylvain F., Zoma, Robert L., Mirza, Imran, Tarbangdo, Felix, Fall, Soukeynatou, Hien, Sansan, Ky, Cesaire, Kambou, Ludovic, Diallo, Alpha Oumar, Aké, Flavien H., Hatcher, Cynthia, Patel, Jaymin C., Novak, Ryan T., Hyde, Terri B., Medah, Isaïe, Soeters, Heidi M., Jalloh, Mohamed F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/ https://www.ncbi.nlm.nih.gov/pubmed/34579975 http://dx.doi.org/10.1016/j.vaccine.2021.09.038

Ejemplares similares

Health workers’ perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso
por: Nkwenkeu, Sylvain F., et al.
Publicado: (2020)

Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt
por: Tartof, Sara, et al.
Publicado: (2013)

Correction: Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt
por: Tartof, Sara, et al.
Publicado: (2017)

Development and Implementation of a Cloud-Based Meningitis Surveillance and Specimen Tracking System in Burkina Faso, 2018
por: Diallo, Alpha Oumar, et al.
Publicado: (2019)

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign
por: Diallo, Alpha Oumar, et al.
Publicado: (2017)

Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt
por: Jackson, Michael L., et al.
Publicado: (2018)

Neisseria meningitidis Serogroup W, Burkina Faso, 2012
por: MacNeil, Jessica R., et al.
Publicado: (2014)

Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys
por: Mbaeyi, Sarah, et al.
Publicado: (2020)

Meningococcal serogroup B vaccines: Estimating breadth of coverage
por: Donald, Robert G. K., et al.
Publicado: (2016)

Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016
por: Soeters, Heidi M., et al.
Publicado: (2017)

Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction
por: Martinelli, Domenico, et al.
Publicado: (2015)

Current Epidemiology of Serogroup W Meningococcal Disease—United States, 2010–2015
por: Soeters, Heidi, et al.
Publicado: (2017)

Are physicians obligated to tell parents about the meningococcal serogroup B vaccine?
por: Robinson, Dr Joan L
Publicado: (2015)

Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
por: Gamougam, Kadidja, et al.
Publicado: (2015)

Parental awareness and utilization of meningococcal serogroup B vaccines in the United States
por: Srivastava, Amit, et al.
Publicado: (2020)

The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae
por: Semchenko, Evgeny A, et al.
Publicado: (2019)

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
por: Rivero-Calle, Irene, et al.
Publicado: (2019)

Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil
por: Tauil, Márcia de Cantuária, et al.
Publicado: (2014)

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
por: Daugla, DM, et al.
Publicado: (2013)

Meningococcal disease serogroup C
por: Dickinson, Félix O, et al.
Publicado: (2012)

Invasive Meningococcal Disease and Meningococcal Serogroup B Vaccination in Adults and Their Offspring: Knowledge, Attitudes, and Practices in Italy (2019)
por: Riccò, Matteo, et al.
Publicado: (2023)

Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
por: SIGNORELLI, C., et al.
Publicado: (2015)

2. Understanding Patient Preferences for Meningococcal Serogroup B Vaccines in the United States
por: Johnson, Reed, et al.
Publicado: (2020)

A comparison of national vaccination policies to prevent serogroup B meningococcal disease
por: Sulis, Giorgia, et al.
Publicado: (2022)

Serogroup W Meningitis Outbreak at the Subdistrict Level, Burkina Faso, 2012
por: Cibrelus, Laurence, et al.
Publicado: (2015)

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine
por: Kristiansen, Paul A, et al.
Publicado: (2013)

Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
por: Kristiansen, Paul A, et al.
Publicado: (2014)

Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015
por: Folaranmi, Temitope, et al.
Publicado: (2015)

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine
por: van Ravenhorst, Mariëtte B., et al.
Publicado: (2018)

Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011–2017
por: Fernandez, Katya, et al.
Publicado: (2019)

Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine
por: Marjuki, Henju, et al.
Publicado: (2019)

Serogroup Y Meningococcal Disease, Colombia
por: Agudelo, Clara Inés, et al.
Publicado: (2008)

Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
por: Hedari, Carine P, et al.
Publicado: (2014)

Evaluation of pneumococcal meningitis clusters in Burkina Faso and implications for potential reactive vaccination
por: Soeters, Heidi M., et al.
Publicado: (2020)

University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018
por: Soeters, Heidi M., et al.
Publicado: (2019)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines
por: Serra, Lidia, et al.
Publicado: (2021)

Molecular characterization of invasive meningococcal isolates in Burkina Faso as the relative importance of serogroups X and W increases, 2008–2012
por: Retchless, Adam C., et al.
Publicado: (2018)

Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis—Burkina Faso, 2014–2015
por: Kambiré, Dinanibè, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2db4gv11tkauko5h87nft3i17n